Calgary, Alberta – Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., today reported promising interim results from its study on MB-204, a new treatment for autism, conducted by the iBraiN Inserm Lab in Tours, France. The study demonstrated that a single oral dose of MB-204 can restore...
Latest News
Calgary, Alberta – Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc.(collectively the “Company” or “Marvel”), is pleased to share part of the final data from its preclinical Rett syndrome study conducted in collaboration with the iBraiN Institute. The study evaluated MB-204, Marvel’s lead compound (10...
Boston, Mass. – A new study by investigators from Mass General Brigham demonstrated that a remote team focused on identifying, educating and prescribing therapy can improve guideline-directed-medical-therapy (GDMT) adherence in patients with type 2 diabetes and high cardiovascular and/or kidney risk. The research team observed that patients who received education...
Chandan Bariya of Sankariya village of Limkheda Taluka was brought to the clinic of Samir Brahmbhat after complaining of severe abdominal pain. Tests demonstrated that the girl was suffering from a rare disorder called Rapunzel syndrome, where an individual pulls one’s hair out and then eats it. This condition normally...
Columbus, Ohio – When Susan Powers went in for surgery to replace her hip in 2018, the last thing on her mind was cancer. But Powers’ pre-surgery blood work alarmed doctors enough that they recommended she see an oncologist immediately. Her daughter, Cheryl Spile, drove her to the hospital, where...
BEDMINSTER, N.J. — Matinas BioPharma (NYSE: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces alignment with the U.S. Food and Drug Administration (FDA) on the design of a single Phase 3 registration trial of MAT2203 in patients with invasive...
How can inflammatory responses be stimulated or inhibited? How do inflammasomes act as inflammatory switches at a molecular level? Prof. Dr. Matthias Geyer from the Institute of Structural Biology at University Hospital Bonn, the transdisciplinary research area “Life & Health” and the ImmunoSensation2 Cluster of Excellence at the University of...
First Patient Dosing Anticipated in Second Half of 2025 Additional Details to be Provided by Webinar in Coming Months MIDDLETON, Mass. — MavriX Bio, a clinical-stage biotechnology company focused on the development of transformative genetic therapies for Angelman syndrome (AS), today announced that the U.S. Food and Drug Administration (FDA) has...
MIDDLETON, Mass. — MavriX Bio, a clinical-stage biotechnology company focused on the development of transformative genetic therapies for Angelman syndrome (AS), today announced that the first patient has been dosed in the Phase 1/2 ASCEND-AS clinical trial of MVX-220, an investigational gene therapy for AS. The ASCEND-AS trial (NCT07181837) represents the...
MIDDLETON, Mass. — MavriX Bio, a clinical-stage biotechnology company focused on the development of transformative genetic therapies for Angelman syndrome (AS), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for MVX-220, an investigational adeno-associated virus (AAV) gene therapy for the treatment of AS. “The...